Slide 1: Emyria Company Update Presentation
ASX RELEASE. 11 June 2026 Emyria Company Update Presentation Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to provide a Company Update which will be presented at the Gold Coast Investment Showcase on 11 June 2026. The update inclu
Slide 2: ASX Release
ASX RELEASE Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care w
Slide 3: Delivering the new paradigm in mental health care
ASX : EMD Delivering the new paradigm in mental health care Company Update June 2026 1 Advanced therapies. Compassionate care.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction.
Slide 5: Who are we?
Who are we? Emyria is addressing a significant and escalating gap in the mental healthcare market Emyria is building a national network of clinics specialising in delivery of Psychedelic Assisted Therapy for PTSD and Treatment Resistant Depression. 3 Advanced therapies. Compassionate care.
Slide 6: Significant momentum in psychedelic drug treatments
Significant momentum in psychedelic drug treatments Recent macro catalysts provide significant tailwinds for Emyria Emyria is well positioned to leverage this momentum, writing the playbook for psychedelic drug delivery SOURCES 1. https://psychedelics.berkeley.edu/clinical-trials-map 4 Advanced ther
Slide 7: Worldwide first mover advantage
Worldwide first mover advantage A Regulated Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions MDMA-assisted therapy This regulation Australia For PTSD change has is the FIRST jurisdiction in created a the world to reschedule Psilocybin-assisted therapy Sig
Slide 8: Patient journey | Treatment model + bed capacity
Patient journey I Treatment model + bed capacity Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up ACTIVE TREATMENT PROTOCOL BED CAPACITY Dosing Dosing Clinic Beds days / week SCREENING Dosing Dosing Day 3 AND Day 1 Day 2 (8 hrs) FOLLOW-UP PREPARATION (8 hrs) (8 hrs) Perth (x2)
Slide 9: Emyria's PTSD program is delivering durable and lasting results
Emyria’s PTSD program is delivering durable and lasting results Durable symptom and quality of life improvement, beyond 12 months Average PCL-5 1 Scores by Visit (up to 12 months follow-up) Typical last treatment Emyria Real-World Data as of Dec 31st 2025 >66% of patients no longer meet criteria for
Slide 10: Major Funders are spending Hundreds of Millions each year on mental health
Major Funders are spending Hundreds of Millions each year on mental health Private Department of Other Health Insurers Veterans’ Affairs Insurers The Government spends Life insurers … paid out more than $2B $300M/yr on veteran mental health each year. 2 $2.2B in 2024 spent by Medibank on mental heal
Slide 11: MDMA-AT cost vs standard of care for PTSD
MDMA-AT cost 1 vs standard of care for PTSD 2, 3 Ongoing care Emyria’s intensive, 6-12 week ~ $33,000 / yr 1 program 1 Neurostimulation (~$3,000) 60 Typical standard of care ~ $60,000 / yr 2 interventions 2 50 Cumulative costs ($1,000s of AUD) 2-week hospital admission 2 (~$24,500) 40 Multidisciplin
Slide 12: Third party funding
Third party funding Reimbursement has commenced for Psychedelic Assisted Therapy Other ad Key funding bodies1,2 Work in progress hoc approvals Case by case We continue to approvals have engage other private occurred from other health insurers, funding bodies workers compensation insurers and other f
Slide 13: Typical timeline to projected clinic profitability
Typical timeline to projected clinic profitability Current Clinic Status Investment Phase Revenue Generation Fit-out & recruitment commences Projected break-even point Months 1-3 Months 4-6 Months 6-9 Months 9-12+ Clinic set-up Open clinic & Dosing day ramp-up Optimise dosing commence screening day
Slide 14: Maturing clinic | Perth Clinic dosing days May 2025 to June 2026
Maturing clinic I Perth Clinic dosing days May 2025 to June 2026 Seasonal Impact –Easter Seasonal Impact - Christmas * Monthly stand alone clinic breakeven. 12 Advanced therapies. Compassionate care.
Slide 15: Regulatory confidence is building
Regulatory confidence is building TGA recommendations grow the pool of therapists that Emyria can recruit 1 In May 26 TGA relaxed rules to include Nurses and Occupational Therapists as a “lead” PAT therapist Minimum therapist requirement Clinical Psychologist Existing Medical Doctor Existing Nurse w
Slide 16: Highly defensible healthcare business
Highly defensible healthcare business Skilled Secure Therapists Drug Supply Third Authorised Party Prescribers Funding Proven Fit-for- Purpose Clinical Model Facilities 14 Advanced therapies. Compassionate care.
Slide 17: Scalable contractor workforce
Scalable contractor workforce Capital light and flexible workforce to support growing clinic utilisation Therapists trained and Authorised Prescribers contracted (AP) 8 approved Perth (x2) ~35 1 in application stage 3 approved Brisbane ~25 2 in application stage 1 approved Melbourne ~25 3 in applica
Slide 18: Potential future treatable conditions
Potential future treatable conditions Significant global research in psychedelic drugs New Treatable Conditions Increase Total Addressable Market SOURCES 1. https://psychedelics.berkeley.edu/clinical-trials-map 16 Advanced therapies. Compassionate care.
Slide 19: Emyria has established versatile delivery infrastructure
Emyria has established versatile delivery infrastructure Infrastructure able to support growing, global research effort into psychedelic drugs More treatment types Third party clinical trials Can support future potential indications Can support clinical trials delivery and treatment types for patien
Slide 20: Emyria Board
Emyria Board Significant Clinical Services & Global Innovation Expertise Greg Hutchinson Dr Michael Winlo Dr Karen Smith Dr Mohit Kaushal Prof Sir John Tooke Executive Chairman Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Health Service Leadership: Research
Slide 21: Corporate Overview
Corporate Overview Share Price, trading history ASX: EMD Trading Information Last Traded Share Price A$0.043 12-Month low / high A$0.021 / 0.078 Shares Outstanding 806,483,233 Unlisted Options (including loyalty options) 310,147,902 Market Capitalisation 1 ~A$35m Last Cash Position 2 ~A$9m Sharehold
Slide 22: Emyria | Summary
Emyria | Summary Significant Total First mover advantage Generating revenue Addressable Market globally AUS + globally Capital Light approach Delivering durable Developing the P-AT to clinics expansion outcomes playbook 20 Advanced therapies. Compassionate care.
Slide 23: Emyria (ASX:EMD) | Executing strongly
Emyria (ASX:EMD) | Executing strongly Delivering on commitments to shareholders Recent Achievements Future Drivers: • 1st Private Health Insurer Funding • 1st DVA approval treatments (Medibank) • Open Sydney Clinic • Opened 2nd Perth Empax Clinic • Additional New Sites Confirmed • Opened Brisbane Em
Slide 24: Contact Information
Contact Information Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Visit Our Investor / Investor Hub Media Inquiries investors@emyria.com